Cancer Immunotherapy: Combinations (C5) 2018
OVERVIEW
Cancer Immunotherapy: Combinations (C5) is organized by Keystone Symposia on Molecular and Cellular Biology and will be held during Mar 23 - 27, 2018 at Queen Elizabeth Hotel, Montreal, Quebec, Canada.
Conference Description :
This meeting helps to address the gaps in knowledge of how and when to combine therapies, and how to integrate immunotherapy into current standard-of-care or novel targeted therapy approaches - both preclinical and clinical. Overall, the objectives of this meeting are to:
• Elucidate rational combinations for immunotherapy
• Discuss preclinical and other models to inform combinatorial approaches
• Understand the relevance of biomarker approaches
• Provide insights into the latest preclinical and clinical data for immunotherapy combinations.
Conference Topics :
• Rational Immunotherapy Combinations: Preclinical Models as Predictive or Responses
• Workshop: Biomarkers and Patient Selection Strategies for Immunotherapy Combinations
• Incorporating Checkpoint Inhibitors into SOC Chemo-and Radiotherapy Regimens
• Combining Immunotherapy with Tyrosine Kinase and Other Signaling Pathway Inhibitors
• Sequencing vs. Combinations: Insights from Biomarker and Preclinical Studies
• Immunotherapy Combinations: Preventing and Managing Resistance to Checkpoint Inhibition and T Cell Exhaustion
• Overcoming T Cell Exclusion and an Immune-Privileged Microenvironment with Combination Approaches
• Vaccines, Oncolytic Viruses, and Cellular Therapies: Towards Combinations
• CTLA-4: Novel Molecules and Approaches to Combinations
• HFrEF: Genetics and Epigenetics
Additional Details will be posted as soon as they are available
Conference Description :
This meeting helps to address the gaps in knowledge of how and when to combine therapies, and how to integrate immunotherapy into current standard-of-care or novel targeted therapy approaches - both preclinical and clinical. Overall, the objectives of this meeting are to:
• Elucidate rational combinations for immunotherapy
• Discuss preclinical and other models to inform combinatorial approaches
• Understand the relevance of biomarker approaches
• Provide insights into the latest preclinical and clinical data for immunotherapy combinations.
Conference Topics :
• Rational Immunotherapy Combinations: Preclinical Models as Predictive or Responses
• Workshop: Biomarkers and Patient Selection Strategies for Immunotherapy Combinations
• Incorporating Checkpoint Inhibitors into SOC Chemo-and Radiotherapy Regimens
• Combining Immunotherapy with Tyrosine Kinase and Other Signaling Pathway Inhibitors
• Sequencing vs. Combinations: Insights from Biomarker and Preclinical Studies
• Immunotherapy Combinations: Preventing and Managing Resistance to Checkpoint Inhibition and T Cell Exhaustion
• Overcoming T Cell Exclusion and an Immune-Privileged Microenvironment with Combination Approaches
• Vaccines, Oncolytic Viruses, and Cellular Therapies: Towards Combinations
• CTLA-4: Novel Molecules and Approaches to Combinations
• HFrEF: Genetics and Epigenetics
Additional Details will be posted as soon as they are available
KEY DATES
23 Mar, 2018
Event Start Date
27 Mar, 2018
Event End Date
SPECIALITIES
OncologyImmunotherapiesSUGGESTED HOTELS
CONFERENCE VENUE
Queen Elizabeth HotelRELATED CONFERENCES & LIVE WEBINARS
Quick Links